Novo mesto, 26 July (STA) - The pharmaceutical group Krka increased its sales revenues by 7% in the first half of the year to EUR 565.3m compared to the same period last year. However, its profit dropped 3% to EUR 90.1m year-on-year, Krka said at a press conference on Thursday.
Similar to the group, the core company's revenues were up 7% as well to
EUR 521.3m, while its profit was 10% lower at EUR 82.9m, according to
unaudited data presented today.
The group's operating profit reached
EUR 117.1m between January and June, down 5% compared to the same period
last year. The company's operating profit was down as well, by 13% to EUR
The group generated 92% of its revenues abroad, while the
share of revenue from foreign markets is even higher for the core company,
which saw 94% of revenue generated abroad.
Nonetheless, the drug
maker saw revenues increase in some markets, most notably in east Europe,
where the sales were up by as much as 25%. This region is also Krka's
biggest market - some 30% of its products are sold there.
first half of the year, the group spent EUR 58m on investments: EUR 26.4m
was invested by the company and EUR 31.6m by its subsidiaries.
data also shows that the number of Krka employees has increased by 3% since
January to a total of 9,203 at the end of June.